PSMD offers a new, high-sensitivity method for detecting microstructural brain abnormalities before they appear on standard MRI scans. By analyzing the movement of water molecules in white matter, researchers—including Dr. Alejandra Morcillo-Nieto, a researcher with the Neuroimaging of Aging and Neurodegenerative Diseases research group at IR Sant Pau—have identified this metric as a potential early-stage biomarker for Alzheimer’s disease, particularly in populations with Down syndrome.
Detecting Subtle White Matter Damage
Standard structural MRI often fails to capture early-stage brain changes. PSMD overcomes this by utilizing diffusion imaging, which tracks water molecule movement across axons and myelin. According to Dr. Morcillo-Nieto, when axonal damage, myelin loss, or microvascular abnormalities arise, this movement becomes heterogeneous. Because PSMD provides an overall value for each individual, it serves as a more practical clinical tool than traditional metrics often reserved for group-level analysis. It can identify white matter abnormalities even in cases where conventional MRI shows no visible lesions or hyperintensities.
Alzheimer’s Progression in Down Syndrome
The application of PSMD to individuals with Down syndrome provides a critical window into disease mechanisms. Research indicates that while PSMD values increase with age across all groups, the increase is particularly pronounced in people with Down syndrome. Data suggests that these differences begin to emerge around age 38—roughly 15 years before clinical Alzheimer’s dementia typically appears. Dr. Morcillo-Nieto notes that while this is a relevant finding, longitudinal studies are the required next step to confirm these trends.
Linking Structural Damage to Cognitive Performance
Higher PSMD values correlate with poorer cognitive performance in both sporadic Alzheimer’s and Down syndrome populations. Researchers utilized neuropsychological tests adapted for individuals with Down syndrome to confirm this link. However, the metric’s utility changes as the disease progresses. While PSMD shows a substantial jump when a patient moves from an asymptomatic to a symptomatic stage, it becomes less precise at distinguishing between prodromal and dementia stages. This suggests that PSMD functions best as an early biomarker rather than a tool for staging disease severity.
Biomarker Associations and Vascular Health
The study highlights that white matter degradation in Alzheimer’s is not the result of a single process. PSMD shows a consistent association with neurofilament light chain (NfL), a protein released during axonal damage. Additionally, the research found links between PSMD and:
- Established Alzheimer’s markers: Beta-amyloid and tau proteins.
- Inflammatory markers: Evidence of glial activation.
- Vascular damage: Correlations with cerebral microbleeds and white matter hyperintensities.
Notably, researchers observed an inverse association between PSMD and pTau181 in sporadic Alzheimer’s cases. The authors suggest this may occur because pTau181 levels can plateau or decline in late-stage disease as neuronal loss reduces the amount of tissue available to release the protein.
Frequently Asked Questions
What is PSMD?
PSMD is a measurement derived from diffusion MRI that analyzes the movement of water molecules in brain tissue to assess the integrity of white matter tracts.
Why is PSMD useful for early Alzheimer’s detection?
It can detect microstructural abnormalities before the damage becomes visible using conventional MRI techniques, making it a potentially valuable early biomarker.
Can PSMD diagnose the stage of dementia?
The research suggests PSMD is most effective as an early biomarker. Once symptoms appear, it is less precise at differentiating between the prodromal and dementia stages of the condition.
Are you interested in the latest developments in neuroimaging and Alzheimer’s research? Subscribe to our newsletter for updates on how clinical imaging is evolving to improve patient care.
Related reading